Medrad

(Booth 8513) Medrad of Warrendale, PA, is set to roll out its new CardiacFlow upgrade for the company's Stellant D CT contrast injection system. Designed to compute customized contrast injection protocols for each cardiac patient, this enhancement permits cardiac imaging during ECG gating.

CardicFlow is powered by Medrad's P3T (Personalized Patient Protocol Technology), which computes custom contrast injection protocols and scan timing for each patient in order to image coronary arteries and chambers of the heart. The upgrade is pending clearance from the U.S. Food and Drug Administration (FDA), and will be shown as a work-in-progress. CardiacFlow is currently available in the U.K. and the rest of Europe, with worldwide availability yet to be determined.

In addition, Medrad will introduce a new patented safety feature for Stellant D, called the XDS extravasation detector technology. XDS couples radiofrequency waves with a physical property called permittivity that directly detects fluid pooling under the patient's skin. Once the system senses mild extravasation, it stops the injection to reduce the risk of a mild occurrence becoming moderate or severe.

XDS received clearance from the FDA in March 2007, and is commercially available.